William G. Nelson, M.D., Ph.D.

Professor - Departments of Oncology, Urology,
Pharmacology and Molecular Sciences, Medicine,
Pathology, and Radiation Oncology and Molecular Radiation Sciences

Diplomate in Internal Medicine, American Board of Internal Medicine (1991)

Diplomate in Medical Oncology, American Board of Internal Medicine (1993)

1980

B.A.- Chemistry

Yale University

1987

M.D. - Medicine

Johns Hopkins University

1987

Ph.D. - Pharmacology

Johns Hopkins University

1987-1990

Residency - Internal Medicine

Johns Hopkins Hospital

1990-1992

Fellowship - Medical Oncology

Johns Hopkins Hospital

1982

Henry Strong Denison Award for Medical Research,
Johns Hopkins University School of Medicine

1987

Sandoz Award for Outstanding Research in Pharmacology,
Johns Hopkins University School of Medicine

1987

Warfield T. Longcope Prize for Excellence in Clinical Medicine,
Johns Hopkins University School of Medicine

1987

Alpha Omega Alpha, Johns Hopkins University School of Medicine

Articles

1. Nelson, C.P., Kidd, L.R., Sauvageot, J., Isaacs, W.B., De Marzo, A.M., Groopman, J.D., Nelson W.G., and Kensler, T.W. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo [4,5-?]pyridine
(N-OH-PhIP) cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 61: 103-109 (2001).

2. Parsons, J.K., Nelson, C.P., Gage, W.R., Nelson, W.G., Kensler, T.W., and De Marzo, A.M. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue.
The Prostate 49: 30-37 (2001).

3. Lin, X., Tascilar, M., Lee, W.-H., Vles, W.J., Lee, B.H., Veeraswamy, R., Asgari, K., Freije, D., van Rees, B., Gage, W.R., Bova, G.S., Isaacs, W.B., Brooks, J.D., DeWeese, T.L., De Marzo, A.M., and Nelson, W.G. Evidence that GSTP1 CpG Island hypermethylation may be selected during human prostatic carcinogenesis. Am J. Pathol. 159: 1815-1826, (2001).

4. Brooks, J.D., Metter, E.J., Chan, D.W., Sokoll, L.J., Landis, P., Nelson, W.G., Carter, H.B., Muller, D., and Andres, R. Plasma selenium level before diagnosis and the risk of prostate cancer development.
J. Urol. 166: 2034-2038 (2001).

5. Jeronimo, C., Usadel, H., Henrique, R., Oliveira, J., Lopes, C., Nelson, W.G., and Sidransky, D. Quantitation of GSTP1 hypermethylation distinguishes between non-neoplastic prostatic tissue and organ confined prostate adenocarcinoma. J. Natl. Cancer Inst. 93: 1747-1752 (2001).

6. Yang, X., Phillips, D.L., Ferguson, A.T., Nelson, W.G., Herman, J.G., and Davidson, N.E. Synergistic activation of functional estrogen receptor (ER)-? by DNA methyltransferase and histone deacetylase inhibition in human ER-?-negative breast cancer cells. Cancer Res. 61: 7025-7029 (2001).

7. DeWeese, T.L., van Der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A.M., Piantadosi, S., Yu, D.C., Chen, Y., Henderson, D.R., Carducci, M.A., Nelson, W.G., and Simons, J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61: 7464-7472 (2001).

8. Lin, X., Asgari, K., Putzi, M.J., Gage, W.R., Yu, X., Cornblatt, B.S., Kumar, A., Piantadosi, S., DeWeese, T.L., De Marzo, A.M., and Nelson, W.G. Reversal of GSTP1 CpG island hypermethylation and reactivation of GSTP1 expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61: 8611-8616 (2001).

9. Zha, S., Gage, W.R., Sauvageot, J., Saria, E.A., Putzi, M.J., Ewing, C.M., Faith, D.A., Nelson, W.G., De Marzo, A.M., and Isaacs, W.B. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 61: 8617-8623 (2001).

10. Parsons, J.K., Gage, W., Nelson, W.G., and De Marzo, A.M. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Urology 58: 619-624 (2001).

11. Ho, G.Y., Knapp, M., Freije, D., Nelson, W.G., Smith, J.R., Carpten, J.D., Bailey-Wilson, J.E., Beaty, T.H., Petersen, G., Xu, J., Kamensky, V., Walsh, P.C., and Isaacs, W.B. Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families.
Int. J. Cancer 98: 938-942 (2002).

12. Bakker, J., Lin, X., and Nelson, W.G. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated ?-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J. Biol. Chem. 277: 22573-22580 (2002).

13. Brooks, J.D., Goldberg, M.F., Nelson, L.A., Wu, D., and Nelson, W.G. Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro.
Cancer Epid. Biom. Prev. 11: 868-875 (2002).

14. Parker, A.R., O'Meally, R.N., Oliver, D.H., Hua, L., Nelson, W.G., DeWeese, T.L., and Eshleman, J.R. 8-hydroxyguanosine repair is defective in some microsatellite stable colorectal cancer cells.
Cancer Res. 62: 7230-7233 (2002).

15. Lin, X., and Nelson, W.G. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells.
Cancer Res. 63: 498-504 (2003).

16. Collis, S.J., Ketner, G.W., Hicks, J.L., Nelson, W.G., De Marzo, A.M., DeWeese, T.L. Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.
Int. J. Rad. Biol. 79: 53-60 (2003).

17. Collis, S.J., Swartz, M.J., Nelson, W.G., and DeWeese, T.L. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.
Cancer Res. 63: 1550-1554 (2003).

18. Gonzalgo, M.L., Pavlovich, C.P., Lee, S.M., and Nelson, W.G. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9: 2673-2677 (2003).

19. Nakayama, M., Bennett, C.J., Hicks, J.L., Epstein, J.I., Platz, E.A., Nelson, W.G., and De Marzo, A.M. Hypermethylation of the human glutathione S-transferase-? gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163: 923-933 (2003).

20. Gonzalgo, M.L., Nakayama, M., Lee, S.M., De Marzo, A.M., and Nelson, W.G. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. In press, Urology (2003).

21. Parker, A.R., O'Meally, R.N., Sahin, F., Su, G.H., Racke, F.K., Nelson, W.G., DeWeese, T.L., and Eshleman, J.R. Defective human MutY phosphorylation exists in colorectal cancer cell lines with wild-type MutY alleles. J. Biol. Chem. 278: 47937-47945 (2003).

22. Yan, L., Nass, S.J., Smith, D., Nelson, W.G., Herman, J.G., and Davidson, N.E. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2: 552-556 (2003).

Reviews

1. Nelson, W.G., De Marzo, A.M., and DeWeese, T.L. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology 57(4 Suppl 1): 39-45 (2001).

2. Nelson, W.G., and Wilding, G. Prostate cancer prevention agent development:
Criteria for candidate chemoprevention agents. Urology 57(4 Suppl 1): 56-63 (2001).

3. De Marzo, A.M., Putzi, M.J., and Nelson, W.G. New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 57(4 Suppl 1): 103-114 (2001).

4. Lieberman, R., Nelson, W.G., Sakr, W.A., Meyskens, F.L., Klein, E.A., Wilding, G., Partin, A.W., Lee, J.J., and Lippman, S.M. Executive summary of the National Cancer Institute workshop: highlights and recommendations. Urology 57(4 Suppl 1): 4-27 (2001).

5. Nelson, W.G. Prostate cancer prevention: the molecular basis.
ASCO Educ. Book 2001: 503-508 (2001).

6. Nelson, W.G., De Marzo, A.M., and DeWeese, T.L. The molecular pathogenesis of prostate cancer: focus on the earliest steps. Eur. Urology 39(Suppl 4), 8-11 (2001).

7. Nelson, W.G., De Marzo, A.M., DeWeese, T.L., Lin, X., Brooks, J.D., Putzi, M.J., Nelson, C.P., Groopman, J.D., and Kensler, T.W. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann. N.Y. Acad. Sci. 952: 135-44 (2001).

8. O'Shaughnessy, J.A., Kelloff, G.J., Gordon, G.B., Dannenberg, A.J., Hong, W.K,, Fabian, C.J., Sigman, C.C., Bertagnolli, M.M., Stratton, S.P., Lam, S., Nelson, W.G., Meyskens, F.L., Alberts, D.S., Follen, M., Rustgi, A.K., Papadimitrakopoulou, V., Scardino, P.T., Gazdar, A.F., Wattenberg, L.W., Sporn, M.B., Sakr, W.A., Lippman, S.M., Von Hoff, D.D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia. Clin. Cancer Res. 8: 314-346 (2002).

9. Isaacs, W., De Marzo, A., and Nelson, W.G. Focus on prostate cancer.
Cancer Cell 2: 113-116 (2002).

10. Partin, A.W., Hanks, G.E., Klein, E.A., Moul, J.W., Nelson, W.G., and Scher, H.I. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 16: 1024-1038 (2002).

11. Partin, A.W., Hanks, G.E., Klein, E.A., Moul, J.W., Nelson, W.G., and Scher, H.I. Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 16: 1218-1224 (2002).

12. Nelson, W.G., DeWeese, T.L., DeMarzo, A.M. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev. 21: 3-16 (2002).

13. Nelson, W. Editorial comment (Re: Valenzuela, M.T. et al. Assessing the use of p16INK4a promoter gene methylation in serum for detection of bladder cancer. Eur. Urology 42: 622-628 (2002)).
Eur. Urology 42: 628-630 (2002).

14. Lin, X., Asgari, K., Putzi, M.J., Gage, W.R., Yu, X., Cornblatt, B.S., Kumar, A., Piantadosi, S., DeWeese, T.L., De Marzo, A.M., and Nelson, W.G. Reversal of GSTP1 CpG island hypermethylation and reactivation of GSTP1 expression in human prostate cancer cells by treatment with procainamide. Qiagen News 6: 21-23 (2002).

15. De Marzo, A.M., Nelson, W.G., Isaacs, W.B., and Epstein, J.I. Pathological and molecular aspects of prostate cancer. Lancet 361: 955-964 (2003).

16. DeWeese, T.L., and Nelson, W.G. Inadequate "caretaker" gene function and human cancer development. Methods Mol. Biol. 222: 249-268 (2003).

17. Nelson, W.G., De Marzo, A.M., and Isaacs, W.B. Prostate cancer.
New Engl. J. Med. 349: 366-381 (2003).

18. De Marzo, A.M., Meeker, A.K., Zha, S., Luo, J., Nakayama, M., Platz, E.A., Isaacs, W.B., and Nelson, W.G. Human prostate cancer precursors and pathobiology. Urology 62: 55-62 (2003).

19. Nakayama, M., Gonzalgo, M.L., Yegnasubramanian, S., Lin, X., De Marzo, A.M., and Nelson, W.G. GSTP1 hypermethylation as a molecular biomarker for prostate cancer.
In press, J. Cell. Biochem. (2003).